

## AGM Results

**Melbourne, Australia; 29 November 2017:** In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises that details of the resolutions and the proxies and votes received in respect of each resolution at its AGM today are set out in the attached proxy and voting summary.

---

### About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing a number of products internally and others via commercial partnerships.

**VivaGel®:** Starpharma's portfolio includes late stage women's health products based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer. VivaGel® formulated as a water based gel and delivered vaginally - VivaGel® BV - has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and has recently completed clinical development for the prevention of recurrent BV. Starpharma has signed a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel® BV in Australia and New Zealand. Starpharma has also developed an antiviral condom which uses VivaGel® in the lubricant. The VivaGel® condom is available in Australia and Canada under the Lifestyles® Dual Protect™ brand and Starpharma also has a number of license agreements to market the VivaGel® condom in other regions, including China and Japan.

**DEP®:** The other major part of Starpharma's pharmaceuticals business is its proprietary DEP® drug delivery platform. Starpharma has both partnered and internal DEP® programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development by the Company. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). In the partnered area, AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of a number of AstraZeneca oncology compounds.

[Starpharma.com](http://Starpharma.com) | [Twitter](https://twitter.com/starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

### Media

#### WE Buchan Consulting

Rebecca Wilson  
Mob: +61 417 382 391  
[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Arthur Chan  
+61 2 9237 2805  
[achan@buchanwe.com.au](mailto:achan@buchanwe.com.au)

### Starpharma

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

**STARPHARMA HOLDINGS LIMITED**  
**Annual General Meeting**  
**Wednesday, 29 November 2017**  
**Voting Results**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	184,086,787 97.04%	3,395,488 1.79%	2,222,150 1.17%	899,407	189,705,505 98.17%	3,534,800 1.83%	918,137	Carried
2 Re-election of Mr Robert Thomas AM	Ordinary	188,436,386 97.16%	3,276,300 1.69%	2,222,150 1.15%	426,423	194,545,534 98.34%	3,276,300 1.66%	426,423	Carried
3 Re-election of Mr Richard Hazleton	Ordinary	189,405,083 97.68%	2,256,103 1.16%	2,251,150 1.16%	448,923	195,183,231 98.68%	2,616,103 1.32%	448,923	Carried
4 Approval of Employee Performance Rights Plan	Ordinary	185,560,867 96.99%	3,525,931 1.84%	2,235,391 1.17%	749,522	191,510,551 98.19%	3,530,931 1.81%	868,252	Carried
5 Issue of Performance Rights- Dr Jacinth Fairley	Ordinary	184,004,166 96.16%	5,126,375 2.68%	2,212,850 1.16%	728,320	189,891,997 97.35%	5,170,687 2.65%	847,050	Carried
6 Alteration of Constitution	Special	190,837,347 98.61%	395,358 0.20%	2,294,805 1.19%	833,749	197,019,150 99.80%	395,358 0.20%	833,749	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.